Sep. 17 at 9:41 PM
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:
$LABT ) develops the Bisphosphocin® class, and Chief Executive Officer Kelvin Cooper, Ph.D., set out how the class works in his presentation to the Life Sciences Virtual Investor Forum, hosted by Virtual Investor Conferences, an OTC Markets Group property, with co-host Zacks Small-Cap Research.
As a new B2i Digital Featured Company, a full company profile is coming soon to https://b2idigital.com/featured-companies
Regarding how the class kills, Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, stated: "The action is extremely rapid, leading to microbial cell rupture and then death in minutes at the concentrations that are easily achieved and even surpassed in what we are targeting to take into the clinic."
The mechanism and the evidence behind it, as Cooper described them:
• The proposed mechanism is disruption of the lipid bilayer membrane of microbes, supported by in vitro mechanistic work including SYTOX Green dye studies and electron microscopy
• Cooper said the class is selective for microbial cells over mammalian cells, which he attributed to charge differences between the two membranes
• Further experimental work is planned to elucidate the mechanism in finer detail, Cooper said
• The mechanism evidence described here is preclinical and based on in vitro studies
Watch the full presentation: https://www.youtube.com/watch?v=-4uaiNZ7bI4
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
$SPRO,
$SCYX,
$XBI